Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has issued an update.
ImmuneOnco Biopharmaceuticals announced a supplemental disclosure regarding its subscription of wealth management products. The company extended its 2023 Subscription and initiated a 2024 Subscription using internal surplus cash reserves. Initially considered immaterial, these transactions were later recognized as discloseable under Chapter 14 of the Listing Rules due to the percentage ratios involved. The company acknowledged its oversight in compliance and has implemented corrective measures to enhance internal controls and training on the Listing Rules.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. operates in the biopharmaceutical industry, focusing on developing innovative cancer immunotherapy products. The company is based in Shanghai, China, and is involved in the research and development of therapies aimed at treating various forms of cancer.
Average Trading Volume: 4,672,559
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.4B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.